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Abstract
Background: Anal canal cancer occasionally accompanies extramammary Paget disease. Although most of them
are squamous cell carcinoma, anal canal adenocarcinoma with neuroendocrine features accompanying secondary
extramammary Paget disease has never been reported.
Case presentation: Here, we report a 76-year-old man presented with pruritus in the perianal area. Investigation
revealed a fist-sized perianal erythema, diffuse liver tumors, and right inguinal lymph node swelling. Pathological
examination of biopsies from the erythema suggested secondary extramammary Paget disease with positive cytokeratin-
7 and -20 expressions and negative GCDFP-15 expression. The anal canal tumor was confirmed by digital examination
and endoscopy. Biopsies from the anal canal tumor, swollen lymph node, and Paget lesion all showed poorly
differentiated adenocarcinoma with neuroendocrine features expressing synaptophysin and chromogranin A.
Serum CEA and NSE levels were high, 809.4 ng/ml and 85.8 ng/ml, respectively. After chemotherapy with modified
FOLFOX6 for 2 months, the Paget lesion disappeared, and the primary anal canal tumor and liver metastases shrunk
remarkably. Serum CEA and NSE levels decreased promptly to within normal ranges.
Conclusions: This is a clinically significant case, as it reveals novel pathological features about anal canal cancer with
secondary Paget disease and successfully treated with modified FOLFOX6. Careful pathological investigation and
appropriate treatment choice are needed for this rare cancer.
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Background
Anal canal cancer is uncommon [1, 2], and approximately
90% of cases are associated with human papillomavirus
(HPV) infection [3]. The incidence of anal canal cancer has
gradually increased over the last few decades [4]. Histo-
logical findings are usually squamous cell carcinoma and
the remaining including adenocarcinoma, neuroendocrine
carcinoma (NEC), melanoma, lymphoma, undifferentiated
carcinoma, and mesenchymal tumors [5, 6]. Anal canal
adenocarcinoma is less associated with HPV infection [7]
and divided into two subtypes according to the presence of
mutations in EGFR signaling pathway and expression of
the immune checkpoint molecules [8].
Anal canal cancer is known to occasionally accompany
with secondary extramammary Paget disease (EPD) [2, 9],
which is characterized histologically as the intraepidermal
proliferation of unique tumor cells (Paget cells) found in
classic mammary Paget disease. Although both primary
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and secondary EPD show similar erosive erythematous
plaque, the prognosis is different between these two EPD
and accurate differential diagnosis is important [10].
Here we present a rare case of adenocarcinoma with
neuroendocrine features of the anal canal accompanying
secondary EPD with diffuse liver involvements, success-
fully treated with an oxaliplatin-containing regimen.
Case presentation
A 76-year-old man with a history of hypertension and
benign prostatic hyperplasia consulted a dermatologist
with a complaint of pruritus in the perianal area. The
doctor diagnosed this area as eczema, and had pre-
scribed Corticosteroid ointment for him for 10 months.
Because his symptom did not improve, he received a col-
onoscopy to check for colorectal malignancy. However, no
anal canal lesion was noticed at that time. Two months
later, multiple liver lesions were incidentally found during
follow-up ultrasonography for his prostatic hyperplasia.
Computed tomography (CT) scan revealed multiple liver
lesions (Fig. 1a) and right inguinal lymph node swelling.
Pathological examination of biopsies obtained from the
perianal erythema showed infiltrating Pagetoid cells and
poorly differentiated adenocarcinoma (Fig. 2a). Immunohis-
tochemistry (IHC) demonstrated malignant cells positive
for cytokeratin (CK)-7 and− 20 (Fig. 2b and c) and negative
for gross cystic disease fluid protein-15 (GCDFP-15)
(Fig. 2d). These findings suggested secondary EPD. The
lymph node was also pathologically diagnosed as a
metastasis. He was referred to our hospital for further
examination and treatment.
On admission, his European Cooperative Oncology
Group performance status was 0. Physical examination
revealed hepatomegaly and erythematous perianal skin
lesion (Fig. 3a). Elastic hard tumor in the anal canal
was palpable by digital examination. Serum carcinoem-
bryonic antigen (CEA), neuron specific γ- enolase (NSE),
and lactate dehydrogenase (LDH) levels were high, with
809.4 ng/mL (normal range, 0 to 5 ng/mL), 85.8 ng/mL
(normal range, 0 to 16.3 ng/mL), and 1176U/L (normal
range, 115 to 245 U/L), respectively. Carbohydrate anti-
gen 19–9 level was normal. Endoscopy showed an ele-
vated tumor of the anal canal like a submucosal tumor
(Fig. 4a and b). Pathological examination revealed poorly
differentiated adenocarcinoma (Fig. 2e) with neuroendocrine
features of positive synaptophysin and chromogranin-A ex-
pressions (Fig. 2f and g). Ki-67 showed a high proliferation
index of 60% (Fig. 2h). A KRAS mutation at codon 12 was
detected in the primary anal canal lesion. The previously di-
agnosed perianal skin lesion and lymph node tumor showed
the same pathological features. Finally, the patient was diag-
nosed with metastatic anal canal adenocarcinoma with neu-
roendocrine features, accompanying secondary EPD.
He received chemotherapy with mFOLFOX6 (oxaliplatin
85mg/m2, bolus 5-FU 400 mg/m2, and folinic acid
200 mg/m2 on day 1 with 46-h infusional 5-FU 2400mg/
m2, every 2 weeks). Soon after treatment, his hepatomegaly
improved day by day. CT scan after 4 courses of mFOL-
FOX6 showed remarkable tumor shrinkage and morpho-
logical changes to homogenous nonenhanced lesions
(Fig. 1b), and the EPD disappeared (Fig. 3b). Serum
levels of LDH, CEA, and NSE decreased promptly to
within normal range (Fig. 5). The primary anal canal le-
sion also responded to the treatment (Fig. 4c and d).
The treatment regimen of mFOLFOX6 was switched to
CAPOX (capecitabine 2000 mg/m2/day for 14 days and
oxaliplatin 130 mg/m2 on day 1, every 3 weeks) due to
thrombus formation around the central venous catheter.
Currently, he is receiving capecitabine plus bevacizumab
together with edoxaban to prevent secondary deep venous
thrombosis after removal of central venous catheter as a
maintenance therapy, and a good partial response with
normal serum tumor markers has been maintained for
more than 11months after the initial treatment.
Discussion
Anal canal cancer is occasionally associated with secondary
EPD. Goldman et al. reported the frequency of secondary
EPD accompanied with anal canal cancer as 33% [11]. The
most common histological findings with secondary EPD
Fig. 1 CT scan showed diffuse liver metastases before treatment (a); cystic morphologically changed after 4 courses of mFOLFOX6 (b)
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are adenocarcinoma and squamous cell carcinoma [12].
Other histological types with secondary EPD are rare and
there are only a few case reports including NEC [13], signet
ring cell carcinoma [14], and mucinous carcinoma [15, 16].
The present case was extremely rare in terms of the par-
ticular histological type accompanied with secondary EPD.
It is not easy to distinguish between secondary and
primary EPD by the clinical and histological findings,
especially if primary EPD invades the epidermis or if an
underlying visceral carcinoma is not apparent. IHC with
CK-7, CK-20, and GCDFP-15 may be useful to distinguish
them. In secondary EPD, the tumor cells are positive for
CK7 and CK20, but negative for GCDFP-15, whereas pri-
mary EPD is commonly positive for GCDFP-15 and CK-7,
but negative for CK-20 [17–21]. A detailed examination to
detect primary tumors should be performed especially in
anorectal lesions such as the present case [10].
In this case, anal canal lesion was missed by previous
colonoscopy. We think the reason for difficulty in detec-
tion is based on the feature that the anal lesion devel-
oped like submucosal tumor. We could detect the lesion
because we had information about secondary Paget dis-
ease and strongly suspected the anal cancer by digital
examination. Most anal canal squamous cell carcinoma
is caused by high risk HPV, anal canal adenocarcinoma
is less related with HPV [7]. This patient did not have
certain sexual history and had KRAS-mutant tumor. Al-
though we did not evaluate HPV infection in this case,
Fig. 2 Pathological examination of extramammary Paget disease (a, b, c, d) and primary lesion of anal canal (e, f, g, h) revealed poorly differentiated
adenocarcinoma with neuroendocrine features. (HE: hematoxylin eosin staining, CK7/CK20: Cytokeratin7/20, GCDFP-15: gross cystic disease fluid protein-15)
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the carcinogenesis of this patient seemed to be less asso-
ciated with HPV infection [8].
There is no report of mixed adenoneuroendocrine car-
cinoma of anal canal cancer, and only one case, involving
an elderly female patient, of NEC with squamous intrae-
pithelial neoplasm of the anal canal has been reported
[22]. The present case was a rare anal canal adenocarcin-
oma with neuroendocrine features, in which prognosis
seemed poor with metastases like those reported in in-
testinal NEC [23, 24].
Fortunately, the patient was successfully treated with
mFOLFOX6, which is a standard treatment for colorectal
adenocarcinoma. CT scan after 4 courses of mFOLFOX6
showed remarkable tumor shrinkage and morphological
changes to homogenous nonenhanced lesions. CT-based
morphological changes correlate with pathologic response
Fig. 4 Endoscopy revealed the primary anal canal lesion like a submucosal tumor (a and b), which shrunk after 4 course of mFOLFOX6 (c and d)
Fig. 3 Paget disease was seen in perianal region before treatment (a) and disappeared after 4 courses of mFOLFOX6 (b)
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and overall survival among patients with colorectal liver
metastases treated with bevacizumab-containing chemo-
therapy [25]. NEC is commonly treated with a platinum-
based doublet, such as etoposide plus cisplatin, following
the treatment guideline for small-cell lung cancer. We
selected mFOLFOX6 regimen for the patient because the
lesion included both components of adenocarcinoma and
NEC. Baba, et al. reported a case of anal canal NEC suc-
cessfully treated with mFOLFOX6 [26]. Further studies are
needed to develop the optimal treatment for these particu-
lar types of cancer.
Conclusions
We reported here the rare case of anal canal adenocarcin-
oma with neuroendocrine features accompanying secondary
EPD, and found mFOLFOX6 to be a very effective treat-
ment. Careful evaluation is necessary for perianal skin lesion
as anal canal cancer with EPD might be hidden.
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